Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Drug interactions between neratinib and trastuzumab

Results for the following 2 drugs:

Interactions between your drugs

There were no interactions found in our database between neratinib and trastuzumab - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.


A total of 228 drugs (949 brand and generic names) are known to interact with neratinib.


A total of 125 drugs (341 brand and generic names) are known to interact with trastuzumab.

Drug and food interactions


neratinib food

Applies to: neratinib

Grapefruit juice can increase the blood levels of neratinib. This may increase the risk and/or severity of side effects such as diarrhea, nausea, vomiting, abdominal pain, mouth sores, loss of appetite, and liver problems. You should avoid the consumption of grapefruit and grapefruit juice during treatment with neratinib. Be sure to take the medication with food at the same time everyday to maintain consistent blood levels and effects. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.


HER2 inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'HER2 inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'HER2 inhibitors' category:

  • neratinib
  • trastuzumab

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.